Article Details

Goldman Sachs Remains a Buy on BridgeBio Pharma (BBIO)

Retrieved on: 2021-05-07 12:33:39

Tags for this article:

Click the tags to see associated articles and topics

Goldman Sachs Remains a Buy on BridgeBio Pharma (BBIO). View article details on hiswai:

Excerpt

Goldman Sachs analyst Paul Choi maintained a Buy rating on BridgeBio Pharma (BBIO) today and set a price target of $80.00. The company's shares ...

Article found on: www.smarteranalyst.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up